SCHEMBL16403760

SCHEMBL16403760

CC(C)(C)OC(=O)NCc1cc(F)cc(-c2csc(C(=O)Nc3ccccc3CC(=O)O)n2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SUCNR1 Q9BXA5 3/20 0.43
▸ HDAC1 Q13547 3/20 0.42
▸ CFD P00746 5/20 0.39
▸ NR1H4 Q96RI1 2/20 0.38
▸ ROCK2 O75116 1/20 0.38
▸ ROCK1 Q13464 1/20 0.38
▸ MEN1 O00255 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ BLM P54132 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ F11 P03951 1/20 0.36
▸ TPSB2 P20231 1/20 0.36
▸ NTRK1 P04629 1/20 0.36
▸ GLS O94925 1/20 0.36
▸ ELOVL1 Q9BW60 1/20 0.35
▸ GRM2 Q14416 1/20 0.35
▸ HDAC3 O15379 2/20 0.35
▸ HDAC2 Q92769 1/20 0.35
▸ HDAC10 Q969S8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17764465 0.85 CFD (0.56) SUCNR1HDAC1CFDNR1H4F11
SCHEMBL16396815 0.83 CFD (0.54) SUCNR1CFDNR1H4MEN1NPC1
SCHEMBL17764428 0.82 SUCNR1 (0.44) SUCNR1HDAC1CFDNR1H4F11
SCHEMBL16396992 0.81 SUCNR1 (0.60) SUCNR1HDAC1CFDNR1H4F11
SCHEMBL17764353 0.81 SUCNR1 (0.41) SUCNR1HDAC1CFDNR1H4F11
SCHEMBL17764316 0.81 SUCNR1 (0.41) SUCNR1HDAC1CFDNR1H4MEN1
SCHEMBL16397314 0.80 SUCNR1 (0.49) SUCNR1HDAC1CFDNR1H4F11
SCHEMBL17764474 0.79 SUCNR1 (0.40) SUCNR1HDAC1CFDNR1H4F11
SCHEMBL16410322 0.79 CFD (0.48) SUCNR1HDAC1CFDNTRK1GRM2
SCHEMBL17764311 0.79 SUCNR1 (0.41) SUCNR1HDAC1CFDNR1H4F11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
EP-3022182-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF Novartis AG (CH) 2016-05-25 — — EP disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 — — WO disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB SUCNR1 4670/4885HDAC1 3377/4885CFD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback